ORIC Pharmaceuticals Inc (ORIC) concluded trading on Thursday at a closing price of $7.97, with 14.44 million shares of worth about $115.1 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -16.89% during that period and on May 29, 2025 the price saw a gain of about 33.50%. Currently the company’s common shares owned by public are about 71.08M shares, out of which, 43.18M shares are available for trading.
Stock saw a price change of 35.78% in past 5 days and over the past one month there was a price change of 40.94%. Year-to-date (YTD), ORIC shares are showing a performance of -1.24% which decreased to -6.78% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.90 but also hit the highest price of $14.67 during that period. The average intraday trading volume for ORIC Pharmaceuticals Inc shares is 766.89K. The stock is currently trading 43.82% above its 20-day simple moving average (SMA20), while that difference is up 44.04% for SMA50 and it goes to -5.03% lower than SMA200.
ORIC Pharmaceuticals Inc (NASDAQ: ORIC) currently have 71.08M outstanding shares and institutions hold larger chunk of about 77.53% of that.
The stock has a current market capitalization of $566.58M and its 3Y-monthly beta is at 1.34. It has posted earnings per share of -$1.88 in the same period. It has Quick Ratio of 12.00 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ORIC, volatility over the week remained 15.94% while standing at 9.21% over the month.
Analysts are in expectations that ORIC Pharmaceuticals Inc (ORIC) stock would likely to be making an EPS of -0.45 in the current quarter, while forecast for next quarter EPS is -0.43 and it is -1.75 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.53 which is -0.36 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.45 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 1.57% while it is estimated to increase by 3.77% in next year. EPS is likely to grow at an annualized rate of 5.83% for next 5-years, compared to annual growth of -15.32% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on October 31, 2024 offering an Overweight rating for the stock and assigned a target price of $20 to it. Coverage by Stifel stated ORIC Pharmaceuticals Inc (ORIC) stock as a Buy in their note to investors on September 06, 2024, suggesting a price target of $20 for the stock. On February 23, 2024, Cantor Fitzgerald Initiated their recommendations, while on September 22, 2023, Wedbush Initiated their ratings for the stock with a price target of $8. Stock get a Buy rating from H.C. Wainwright on March 23, 2023.
